To investigate the bribery of foreign pharmaceutical enterprises

After GlaxoSmithKline was put on file by the public security organs for investigation, AstraZeneca, the world's leading pharmaceutical company, was also investigated by the police Chinese police visited AstraZeneca's Shanghai Office on Friday and took away a sales employee (Beijing times, July 23)   GSK (GlaxoSmithKline) the "ripples" caused by this stone seem to be dragging foreign counterparts into the mire of investigation one by one: on July 16, the Shanghai offices of Belgium youshibi Pharmaceutical Co., Ltd and Switzerland Novartis Pharmaceutical Co., Ltd were visited by the industrial and commercial departments respectively; on July 19, many famous pharmaceutical enterprises, such as AstraZeneca, Pfizer, Bayer and Roche, also welcomed the investigation of the industrial and commercial departments Forensics..   Let's look at two figures: first, the amount of imported drugs and the average unit price have soared in recent years According to the data provided by the customs information network, from 2006 to 2011, the amount of imported drugs increased by an average of 34% annually, about 10 percentage points higher than the growth rate of the domestic pharmaceutical industry, and the average unit price of imported drugs increased by 19.18% year on year Liang Hong, vice president of GSK China, who has been taken away by the police, said in an interview with CCTV that the operating cost mainly based on commercial bribery accounts for about 20% - 30% of the composition of drug price Taking the ex factory price of 140 yuan hepudine as an example, the actual cost of drugs without considering research and development costs is less than 84 yuan When foreign medicine came into China, it also became the pusher of "expensive doctor" to "do as the Romans do" It's only because of the unscrupulous businessmen that they can persuade the public?   According to McKinsey, China's total health care spending will rise to $1 trillion by 2020, from $357 billion in 2011 For foreign funded pharmaceutical enterprises, this is a fat "cake", and commercial bribery has obviously become the golden key to pry this "cake" In the GSK scandal, most of the funds drawn from travel agencies are believed to be used for government public relations Foreign funded pharmaceutical enterprises call it "big projects", including new drug access, joint government promotion, access to medical insurance and other links - these are big projects of "burning money", and also the tacit rules of foreign funded pharmaceutical enterprises Compared with medical treatment, to worship Bodhisattva in the "Temple" of the authority is the "big hand" in commercial bribery   According to reports, some people in the industry said that "if the product is to be put on the market, the batch number and approval documents in the early stage, the sales channel development in the later stage, and the profit margin of the sales terminal, the Bodhisattva of at least two digits (sometimes even hundreds) in size should be worshipped" Finally, the "operation cost" mainly based on commercial bribery should be spread out in the form of "black gold" to the medical bills of end consumers   If there is a bribe, there must be a bribe Which Bodhisattvas have collected "incense money" from foreign pharmaceutical companies such as GSK is more important than finding out several speculators What kind of institutional prevention system should be set up to ensure that the rights and interests such as drug registration and approval can not be confused? This is a more rational thing than spitting at foreign drug companies that do not abide by the law.